Methods and materials for treating diabetes or liver steatosis

Patent metadata

Field	Value
Publication number	US-2016243152-A1
Application number	US-201415023069-A
Country	US
Kind code	A1
Filing date	Aug 29, 2014
Priority date	Sep 19, 2013
Publication date	Aug 25, 2016
Grant date	—

Abstract

This document provides methods and materials for treating diabetes and/or liver steatosis. For example, methods for using compositions containing a potato polysaccharide preparation to reduce one or more symptoms of diabetes or liver steatosis are provided. In some cases, a composition containing a potato polysaccharide preparation provided herein can be used to treat fatty liver disease.

First claim

What is claimed is:

1 . A method for treating diabetes, wherein said method comprises:
(a) identifying a mammal with diabetes, and (b) administering to said mammal a composition comprising a potato polysaccharide preparation obtained from raw potatoes, wherein the severity of a symptom of said diabetes is reduced.

2 . The method of claim 1 , wherein said composition comprises said potato polysaccharide preparation in an amount that results in between 0.05 mg and 50 mg of the potato polysaccharide component of said potato polysaccharide preparation being administered to said mammal per kg of body weight of said mammal.

3 . The method of claim 1 , wherein said composition comprises between 1 mg and 100 mg of said potato polysaccharide preparation.

4 . The method of claim 1 , wherein said composition comprises between 6 mg and 20 mg of said potato polysaccharide preparation.

5 . The method of claim 1 , wherein said composition comprises between 1 mg and 100 mg of the potato polysaccharide component of said potato polysaccharide preparation.

6 . The method of claim 1 , wherein said composition comprises between 6 mg and 20 mg of the potato polysaccharide component of said potato polysaccharide preparation.

7 . The method of claim 1 , wherein said composition is in the form of a tablet.

8 . The method of claim 1 , wherein said composition comprises alpha lipoic acid.

9 . The method of claim 1 , wherein said composition comprises alpha tocopherol.

10 . The method of claim 1 , wherein said potato polysaccharide preparation is in an amount that results in between 0.075 mg and 0.5 mg of the potato polysaccharide component of said potato polysaccharide preparation being administered to said mammal per kg of body weight of said mammal.

11 . The method of claim 1 , wherein at least about 80 percent of said potato polysaccharide preparation is potato polysaccharide.

12 . The method of claim 1 , wherein at least about 90 percent of said potato polysaccharide preparation is potato polysaccharide.

13 . The method of claim 1 , wherein at least about 95 percent of said potato polysaccharide preparation is potato polysaccharide.

14 . The method of claim 1 , wherein said mammal is a human.

15 . A method for treating a fatty liver disease, wherein said method comprises:
(a) identifying a mammal with a fatty liver disease, and (b) administering to said mammal a composition comprising a potato polysaccharide preparation obtained from raw potatoes, wherein the severity of a symptom of said fatty liver disease is reduced.

16 . The method of claim 15 , wherein said composition comprises said potato polysaccharide preparation in an amount that results in between 0.05 mg and 50 mg of the potato polysaccharide component of said potato polysaccharide preparation being administered to said mammal per kg of body weight of said mammal.

17 . The method of claim 15 , wherein said composition comprises between 1 mg and 100 mg of said potato polysaccharide preparation.

18 . The method of claim 15 , wherein said composition comprises between 6 mg and 20 mg of said potato polysaccharide preparation.

19 . The method of claim 15 , wherein said composition comprises between 1 mg and 100 mg of the potato polysaccharide component of said potato polysaccharide preparation.

20 . The method of claim 15 , wherein said composition comprises between 6 mg and 20 mg of the potato polysaccharide component of said potato polysaccharide preparation.

21 . The method of claim 15 , wherein said composition is in the form of a tablet.

22 . The method of claim 15 , wherein said composition comprises alpha lipoic acid.

23 . The method of claim 15 , wherein said composition comprises alpha tocopherol.

24 . The method of claim 15 , wherein said potato polysaccharide preparation is in an amount that results in between 0.075 mg and 0.5 mg of the potato polysaccharide component of said potato polysaccharide preparation being administered to said mammal per kg of body weight of said mammal.

25 . The method of claim 15 , wherein at least about 80 percent of said potato polysaccharide preparation is potato polysaccharide.

26 . The method of claim 15 , wherein at least about 90 percent of said potato polysaccharide preparation is potato polysaccharide.

27 . The method of claim 15 , wherein at least about 95 percent of said potato polysaccharide preparation is potato polysaccharide.

28 . The method of claim 15 , wherein said mammal is a human.

Assignees

• Univ New York State Res Found

Inventors

• Stefano George B
• Kream Richard
• Mantione Kirk J

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61K36/39

  Convolvulaceae (Morning-glory family), e.g. bindweed · CPC title